Biology of Blood and Marrow Transplantation最新文献

{"title":"Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases","authors":"Juliana Folloni Fernandes ,&nbsp;Samantha Nichele ,&nbsp;Leonardo Javier Arcuri ,&nbsp;Lisandro Ribeiro ,&nbsp;Gabriele Zamperlini-Netto ,&nbsp;Gisele Loth ,&nbsp;Ana Luiza Melo Rodrigues ,&nbsp;Cilmara Kuwahara ,&nbsp;Adriana Koliski ,&nbsp;Joanna Trennepohl ,&nbsp;Julia Lopes Garcia ,&nbsp;Liane Esteves Daudt ,&nbsp;Adriana Seber ,&nbsp;Alessandra Araujo Gomes ,&nbsp;Anders Fasth ,&nbsp;Ricardo Pasquini ,&nbsp;Nelson Hamerschlak ,&nbsp;Vanderson Rocha ,&nbsp;Carmem Bonfim","doi":"10.1016/j.bbmt.2020.07.003","DOIUrl":"10.1016/j.bbmt.2020.07.003","url":null,"abstract":"<div><p>Allogeneic hematopoietic stem cell transplantation (HCT) can cure primary immunodeficiency diseases (PID). When a HLA-matched donor is not available, a haploidentical family donor may be considered. The use of T cell-replete haploidentical HCT with post-transplantation cyclophosphamide (haplo-PTCy) in children with PID has been reported in few case series. A donor is usually readily available, and haplo-PTCy can be used in urgent cases. We studied the outcomes of 73 patients with PID who underwent haplo-PTCy, including 55 patients who did so as a first transplantation and 18 who did so as a salvage transplantation after graft failure of previous HCT. The median patient age was 1.6 years. Most of the children were male (n = 54) and had active infection at the time of transplantation (n = 50); 10 children had severe organ damage. The diagnosis was severe combined immunodeficiency (SCID) in 34 patients and non-SCID in 39 (Wiskott-Aldrich syndrome; n = 14; chronic granulomatous disease, n = 10; other PID, n = 15). The median duration of follow-up of survivors was 2 years. The cumulative incidence of neutrophil recovery was 88% in the SCID group and 84% in non-SCID group and was 81% for first transplantations and 83% after a salvage graft. At 100 days, the cumulative incidence of acute GVHD grade II-IV and III-IV was 33% and 14%, respectively. The majority of patients reached 200/μL CD4⁺ and 1000/μL CD3⁺ cell counts between 3 and 6 months. The estimated 2-year overall survival was 66%; it was 64% for SCID patients and 65% for non-SCID patients and 63% for first HCT and 77% for salvage transplantations. Twenty-five patients died, most of them due to infection early after transplantation (before 100 days). In conclusion, haplo-PTCy is a feasible procedure, can cure two-thirds of children with PID, and can be used as rescue treatment for previous graft failure.</p><p>© 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1923-1929"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38143802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant","authors":"Joyce J. Johnsrud ,&nbsp;Isabelle T. Nguyen ,&nbsp;Walter Domingo ,&nbsp;Balasubramanian Narasimhan ,&nbsp;Bradley Efron ,&nbsp;Janice (Wes) Brown","doi":"10.1016/j.bbmt.2020.07.002","DOIUrl":"10.1016/j.bbmt.2020.07.002","url":null,"abstract":"<div><p>Despite effective therapies, cytomegalovirus (CMV) continues to have a significant impact on morbidity and mortality in hematopoietic cell transplant recipients. At particular risk are recipients of alternative grafts such as umbilical cord blood (UCB), haploidentical transplants (haplo), or patients conditioned with T-cell depleting regimens such as anti-thymocyte globulin (ATG). With the approval of letermovir, its impact on high-risk patients is of particular interest. To evaluate the impact of letermovir prophylaxis at our center, we performed a retrospective analysis of 114 high-risk patients who received letermovir as prophylaxis (LET PPX) between January 2018 through December 2019, including 30 UCB and 22 haplo recipients, compared with 637 historical controls with comparable risk between January 2013 and December 2019. By post-transplant day 100 (D+100), letermovir prophylaxis significantly decreased the incidence of both CMV DNAemia compared with controls (45.37% versus 74.1%; <em>P</em> &lt; .001) and clinically significant CMV infection (12.04% versus 48.82%; <em>P</em> &lt; .001). The impact of LET PPX was even more profound on the incidence of clinically significant CMV infection (CSI), defined as the administration of antiviral therapy as preemptive therapy for CMV DNAemia or treatment for CMV disease. CSI was significantly lower in haplo recipients on LET PPX compared with controls (13.64% versus 73.33%; <em>P</em>= .02) and UCB recipients on LET PPX compared with controls (3.45% versus 37.5%; <em>P</em> &lt; .001). No patients on LET primary PPX developed CMV disease in any treatment group by D+100 compared with controls (0% versus 5.34%, respectively; <em>P</em> = .006). Patients on LET PPX had fewer hospitalizations involving initiation of anti-CMV therapy compared with controls (0.93% versus 15.23%, respectively). Our analysis of the largest cohort of patients at high risk for CMV reactivation published to date demonstrates that letermovir prophylaxis significantly reduces the number of patients who receive CMV-active antiviral therapy for either DNAemia or disease due to CMV.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1963-1970"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38143803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling","authors":"Sarah A. Holstein ,&nbsp;Alan Howard ,&nbsp;David Avigan ,&nbsp;Manisha Bhutani ,&nbsp;Adam D. Cohen ,&nbsp;Luciano J. Costa ,&nbsp;Madhav V. Dhodapkar ,&nbsp;Francesca Gay ,&nbsp;Nicole Gormley ,&nbsp;Damian J. Green ,&nbsp;Jens Hillengass ,&nbsp;Neha Korde ,&nbsp;Zihai Li ,&nbsp;Sham Mailankody ,&nbsp;Paola Neri ,&nbsp;Samir Parekh ,&nbsp;Marcelo C. Pasquini ,&nbsp;Noemi Puig ,&nbsp;G. David Roodman ,&nbsp;Mehmet Kemal Samur ,&nbsp;Philip L. McCarthy","doi":"10.1016/j.bbmt.2020.06.011","DOIUrl":"10.1016/j.bbmt.2020.06.011","url":null,"abstract":"<div><p>The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled “Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.” This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. In this report, we provide a summary of the workshop and discuss future directions.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages e247-e255"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.06.011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38094484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging in Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome","authors":"Sherwin S. Chan ,&nbsp;Antonio Colecchia ,&nbsp;Rafael F. Duarte ,&nbsp;Francesca Bonifazi ,&nbsp;Federico Ravaioli ,&nbsp;Jean Henri Bourhis","doi":"10.1016/j.bbmt.2020.06.016","DOIUrl":"10.1016/j.bbmt.2020.06.016","url":null,"abstract":"<div><p>Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of hematopoietic cell transplantation. Early diagnosis and, subsequently, earlier intervention have been shown to be beneficial to clinical outcomes. Diagnostic criteria from the European Society for Blood and Marrow Transplantation include recommendations on the use of imaging for diagnosis. This review discusses evidence on the use of imaging in the management of VOD/SOS and how imaging biomarkers can contribute to earlier diagnosis/treatment.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1770-1779"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.06.016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38097023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines for Cord Blood Unit Thaw and Infusion","authors":"Andromachi Scaradavou ,&nbsp;Scott T Avecilla ,&nbsp;Joann Tonon ,&nbsp;Ioannis Politikos ,&nbsp;Mitchell E. Horwitz ,&nbsp;Joanne Kurtzberg ,&nbsp;Filippo Milano ,&nbsp;Juliet N Barker ,&nbsp;American Society for Transplantation and Cellular Therapy Cord Blood Special Interest Group","doi":"10.1016/j.bbmt.2020.06.018","DOIUrl":"10.1016/j.bbmt.2020.06.018","url":null,"abstract":"","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1780-1783"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.06.018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38098458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Who Enrolls in an Online Cancer Survivorship Program? Reach of the INSPIRE Randomized Controlled Trial for Hematopoietic Cell Transplantation Survivors","authors":"Jean C. Yi ,&nbsp;Brie Sullivan ,&nbsp;Wendy M. Leisenring ,&nbsp;Navneet S. Majhail ,&nbsp;Heather Jim ,&nbsp;Alison Loren ,&nbsp;Joseph Uberti ,&nbsp;Victoria Whalen ,&nbsp;Mary E.D. Flowers ,&nbsp;Stephanie J. Lee ,&nbsp;Katie Maynard ,&nbsp;Karen L. Syrjala","doi":"10.1016/j.bbmt.2020.06.017","DOIUrl":"10.1016/j.bbmt.2020.06.017","url":null,"abstract":"<div><p>The internet can be a valuable tool in delivering survivorship care to hematopoietic cell transplantation (HCT) cancer survivors. We describe the reach of INSPIRE, an Internet and social media-based randomized controlled trial, to address healthcare and psychosocial needs of HCT survivors. All survivors 2-10 years after HCT for hematologic malignancy or myelodysplasia from 6 transplantation centers in the US were approached by mail and follow-up calls. Eligible participants had access to the Internet, an email address, and did not have active disease in the past 2 years. We used logistic regression to determine characteristics of eligible survivors who were more or less likely to enroll. Of 2578 eligible HCT survivors, 1065 (41%) enrolled in the study. The mean age of enrollees was 56.3 ± 12.6 years (range, 19 to 89 years), 52% were male, and 94% were white. Survivors less likely to enroll included those who were male, age &lt;40 years, and who received an autologous transplant (all <em>P</em> &lt; .001). Compared with white survivors, African Americans were less likely to enroll (<em>P</em> &lt; .001), whereas Native Americans/Alaska Natives were more likely to join the study (<em>P</em> = .03). The reach of the INSPIRE program was broad, including to survivors who traditionally have less access to resources, such as Native Americans/Alaskan Natives and rural residents. Strategies are still needed to improve the enrollment of online studies of survivorship resources for males, young adults, African American, and autologous HCT survivors because their use may improve outcomes.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1948-1954"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.06.017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38098460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Officers and Directors of ASTCT","authors":"","doi":"10.1016/S1083-8791(20)30548-6","DOIUrl":"https://doi.org/10.1016/S1083-8791(20)30548-6","url":null,"abstract":"","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Page A10"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1083-8791(20)30548-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137414308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fludarabine, Campath, and Low-Dose Cyclophosphamide (FCClow) with or without TBI Conditioning Results in Excellent Transplant Outcomes in Children with Severe Aplastic Anemia","authors":"Ravi M. Shah ,&nbsp;Tony H. Truong ,&nbsp;Michel T. Leaker ,&nbsp;Nicola A.M. Wright ,&nbsp;Doan Le ,&nbsp;MacGregor Steele ,&nbsp;Aisha A.K. Bruce ,&nbsp;Sunil Desai ,&nbsp;Gregory M.T. Guilcher ,&nbsp;Victor Lewis","doi":"10.1016/j.bbmt.2020.06.027","DOIUrl":"10.1016/j.bbmt.2020.06.027","url":null,"abstract":"<div><p>Various reduced-intensity conditioning regimens are in use for allogeneic hematopoietic cell transplant (HSCT) in patients with idiopathic severe aplastic anemia (SAA). We describe the use of fludarabine, Campath, and low-dose cyclophosphamide (FCC^low) conditioning in 15 children undergoing related or unrelated donor transplants. Total body irradiation (TBI) of 2 Gy was added for unrelated donor HSCT. At a median follow-up of 2.3 years, the failure-free survival was 100%, with low rates of infection and toxicity. There was no occurrence of grade III to IV acute graft-versus-host disease (GVHD). All patients had full donor myeloid chimerism post-HSCT, even with mixed chimerism in the T cell lineage. The absence of chronic GVHD and long-term stable mixed donor T cell chimerism confirms immune tolerance following FCC^low (± TBI) conditioned transplantation in children with SAA.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1900-1905"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.06.027","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38138134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation","authors":"Jiaqi Fang ,&nbsp;Yiqi Su ,&nbsp;Phaedon D. Zavras ,&nbsp;Amit D. Raval ,&nbsp;Yuexin Tang ,&nbsp;Miguel-Angel Perales ,&nbsp;Sergio Giralt ,&nbsp;Anat Stern ,&nbsp;Genovefa A. Papanicolaou","doi":"10.1016/j.bbmt.2020.06.025","DOIUrl":"10.1016/j.bbmt.2020.06.025","url":null,"abstract":"<div><p>Cytomegalovirus (CMV) viremia occurs in 40% to 80% of CMV-seropositive (R+) recipients of allogeneic hematopoietic cell transplantation (HCT). The preemptive therapy (PET) strategy has reduced the risk of CMV end-organ disease (EOD) and associated mortality but may lead to substantial healthcare resource utilization (HCRU) and costs. Real-world data on the economic impact of PET is relevant for the evaluation of alternative strategies for CMV management. We examined the impact of clinically significant CMV treated with PET on inpatient length of stay (LOS), number of readmissions, and associated costs from day 0 through day 180 post-HCT.</p><p>This was a retrospective study of R+ adults who underwent peripheral blood or marrow allogeneic HCT at Memorial Sloan Kettering Cancer Center between March 2013 and December 2017. Patients were routinely screened for CMV by qPCR and received PET according to institutional standards of care. Data were extracted from electronic medical records and hospital databases. Itemized cost data per patient were obtained from the Vizient database, adjusted to 2017 dollars using inflation indices. Study outcomes included HCRU evaluated by inpatient LOS and inpatient cost in patients who received PET for clinically significant CMV (PET group) compared with those who did not receive PET (no PET group) and the frequency and cost of CMV-related readmissions compared with non CMV-related readmissions. We used generalized linear models to examine the incremental HCRU and costs associated with PET controlling for other potential factors. Of 357 patients, PET was initiated in 208 (58.3%), at a median of 35 days after HCT. By day 180, 23 patients (6.4%) had developed CMV EOD and 3 (.8%) had died of CMV. Compared with the no PET group, the PET group had a longer LOS for HCT admission (<em>P</em> = .0276), longer total LOS by day 180 (<em>P</em> = .0001), a higher number of readmissions (<em>P</em> = .0001), a higher mean inpatient cost for HCT admission ($189,389 versus $151,646; <em>P</em> = .0133), and a higher total inpatient cost ($297,563 versus $205,815; <em>P</em> &lt; .0001). Among PET recipients, CMV-related readmissions were associated with higher mean cost per episode compared with non CMV-related readmissions ($165,455 versus $89,419; <em>P</em> = .005). CMV-related readmissions comprised 40.6% of total all-cause readmissions and incurred 55.9% of total all-cause readmission costs in PET recipients. Our data show that patients treated with currently available PET had greater inpatient HCRU and cost, by day 180 compared with patients who did not receive PET. The cost of CMV-related readmissions accounted for 56% of total readmission cost among PET recipients. Future studies are needed to examine the cost-effectiveness of alternative strategies for CMV management.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1937-1947"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.06.025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38138527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation","authors":"L. Farina ,&nbsp;F. Barretta ,&nbsp;L. Scarfò ,&nbsp;B Bruno ,&nbsp;F. Patriarca ,&nbsp;AM. Frustaci ,&nbsp;M. Coscia ,&nbsp;C. Salvetti ,&nbsp;G. Quaresmini ,&nbsp;R. Fanin ,&nbsp;F. Onida ,&nbsp;M. Magagnoli ,&nbsp;F. Zallio ,&nbsp;D. Vallisa ,&nbsp;G. Reda ,&nbsp;A Ferrario ,&nbsp;P. Corradini ,&nbsp;M Montillo","doi":"10.1016/j.bbmt.2020.06.032","DOIUrl":"10.1016/j.bbmt.2020.06.032","url":null,"abstract":"<div><p>Refractory/early relapsed and 17p deletion/p53 mutation (del(17p)/TP53mut)-positive chronic lymphocytic leukemia (CLL) has been conventionally considered a high-risk disease, potentially eligible for treatment with allogeneic stem cell transplantation (alloSCT). In this multicenter retrospective analysis of 157 patients, we compared the outcomes of patients with high-risk CLL treated with alloSCT, a B-cell receptor pathway inhibitor (BCRi), and both. Seventy-one patients were treated with BCRis, 67 patients underwent reduced-intensity conditioning alloSCT, and 19 received alloSCT with a BCRi before and/or after transplantation. Inverse probability of treatment weighting analyses were performed to compare the alloSCT and no-alloSCT groups; in the 2 groups, 5-year OS, PFS, and cumulative incidence of nonrelapse mortality (NRM) and relapse were 40% versus 60% (<em>P</em> = .096), 34% versus 17% (<em>P</em> = .638), 28% versus 5% (<em>P</em> = .016), and 38% versus 83% (<em>P</em> = .005), respectively. Patients treated with alloSCT plus BCRi had a 3-year OS of 83%. The 3-year OS and NRM by year of alloSCT, including patients treated with BCRi, were 53% and 17% in 2000 to 2007, 55% and 30% in 2008 to 2012, and 72% and 18% in 2013 to 2018. In conclusion, the combination of pathway inhibitors and alloSCT is feasible and may further improve the outcome of high-risk CLL patients.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages e256-e262"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.06.032","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38143807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}